phase 1_completion
saveOncoNano Medicine Inc — cemiplimab (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Basal Cell Carcinoma (Basal Cell Epithelioma), Bladder Cancer, Carcinomas, Cervical Cancer, Cutaneous Squamous Cell Carcinoma (cSCC), Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Head And Neck Squamous Cell Carcinoma (HNSC), Lymphoma, Mantle Cell Lymphoma, Melanoma, Non-Hodgkin Lymphoma, Skin Cancer, Solid Tumor, Triple-Negative Breast Cancer (TNBC), Uveal Melanoma
Data sources
globaldata
Found something off?
drug timeline · 8
- phase 2 completionRegeneron Pharmaceuticals Inc — cemiplimab (Phase II Trial Completion)Apr 30, 2026 · 158d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 29, 2025 · 341d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalOct 8, 2025 · 362d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 5, 2024 · 913d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalMar 6, 2024 · 943d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1256d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalApr 28, 2023 · 1256d ago
- approvalLIBTAYO (CEMIPLIMAB-RWLC) — FDA approvalNov 8, 2022 · 1427d ago
related news · 2
🐶 often sniffed alongside
top 8- tagApproval60 co-mentions · 15 sources
- drugLIBTAYO60 co-mentions · 15 sources
- tagOncology12 co-mentions · 3 sources
- tagPulmonology4 co-mentions · 1 sources
- tagNSCLC3 co-mentions · 1 sources
- tagBreast Cancer3 co-mentions · 1 sources
- tagMelanoma3 co-mentions · 1 sources
- tagColorectal Cancer2 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that